Ewelina Kazimierczyk1, Andrzej Eljaszewicz2, Paula Zembko2, Ewa Tarasiuk1, Malgorzata Rusak3, Agnieszka Kulczynska-Przybik4, Marta Lukaszewicz-Zajac5, Karol Kaminski6, Barbara Mroczko7, Maciej Szmitkowski5, Milena Dabrowska3, Bozena Sobkowicz1, Marcin Moniuszko8, Agnieszka Tycinska9. 1. Department of Cardiology, Medical University of Bialystok, Białystok, Poland. 2. Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Białystok, Poland. 3. Department of Hematological Diagnostics, Medical University of Bialystok, Białystok, Poland. 4. Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Białystok, Poland. 5. Department of Biochemical Diagnostics, Medical University of Bialystok, Białystok, Poland. 6. Department of Cardiology, Medical University of Bialystok, Białystok, Poland; Department of Population Medicine and Prevention of Civilization Diseases, Medical University of Bialystok, Białystok, Poland. 7. Department of Neurodegeneration Diagnostics, Medical University of Bialystok, Białystok, Poland; Department of Biochemical Diagnostics, Medical University of Bialystok, Białystok, Poland. 8. Department of Regenerative Medicine and Immune Regulation, Medical University of Bialystok, Białystok, Poland; Department of Allergology and Internal Medicine, Medical University of Bialystok, Białystok, Poland. 9. Department of Cardiology, Medical University of Bialystok, Białystok, Poland. Electronic address: agnieszka.tycinska@gmail.com.
Abstract
BACKGROUND: Acute myocardial infarction (AMI) causes irreversible myocardial damage and release of inflammatory mediators, including cytokines, chemokines and miRNAs. We aimed to investigate changes in the levels of cytokines (IL-6, TNF-α and IL-10), miRNAs profiles (miR-146 and miR-155) and distribution of different monocyte subsets (CD14++CD16-, CD14++CD16+, CD14+CD16++) in the acute and post-healing phases of AMI. METHODS: In eighteen consecutive AMI patients (mean age 56.78 ± 12.4 years, mean left ventricle ejection fraction - LVEF: 41.9 ± 9.8%), treated invasively, monocyte subsets frequencies were evaluated (flow cytometry), cytokine concentrations were analyzed (ELISA) as well as plasma miRNAs were isolated twice - on admission and after 19.2 ± 5.9 weeks of follow-up. Measurements were also performed among healthy volunteers. RESULTS: AMI patients presented significantly decreased frequencies of classical cells in comparison to healthy controls (median 71.22% [IQR: 64.4-79.04] vs. 84.35% [IQR: 81.2-86.7], p = 0.001) and higher percent of both intermediate and non-classical cells, yet without statistical significance (median 6.54% [IQR: 5.14-16.64] vs. 5.87% [IQR: 4.48-8.6], p = 0.37 and median 5.99% [IQR: 3.39-11.5] vs. 5.26% [IQR: 3.62-6.2], p = 0.42, respectively). In AMI patients both, analyzed plasma miRNA concentrations were higher than in healthy subjects (miR-146: median 5.48 [IQR: 2.4-11.27] vs. 1.84 [IQR: 0.87-2.53], p = 0.003; miR-155: median 25.35 [IQR: 8.17-43.15] vs. 8.4 [IQR: 0.08-16.9], p = 0.027, respectively), and returned back to the values found in the control group in follow-up. miR-155/miR-146 ratio correlated with the frequencies of classical monocytes (r=0.6, p = 0.01) and miR-155 correlated positively with the concentration of inflammatory cytokines - IL-6 and TNF-α. CONCLUSIONS: These results may suggest cooperation of both pro-inflammatory and anti-inflammatory signals in AMI in order to promote appropriate healing of the infarcted myocardium.
BACKGROUND:Acute myocardial infarction (AMI) causes irreversible myocardial damage and release of inflammatory mediators, including cytokines, chemokines and miRNAs. We aimed to investigate changes in the levels of cytokines (IL-6, TNF-α and IL-10), miRNAs profiles (miR-146 and miR-155) and distribution of different monocyte subsets (CD14++CD16-, CD14++CD16+, CD14+CD16++) in the acute and post-healing phases of AMI. METHODS: In eighteen consecutive AMI patients (mean age 56.78 ± 12.4 years, mean left ventricle ejection fraction - LVEF: 41.9 ± 9.8%), treated invasively, monocyte subsets frequencies were evaluated (flow cytometry), cytokine concentrations were analyzed (ELISA) as well as plasma miRNAs were isolated twice - on admission and after 19.2 ± 5.9 weeks of follow-up. Measurements were also performed among healthy volunteers. RESULTS: AMI patients presented significantly decreased frequencies of classical cells in comparison to healthy controls (median 71.22% [IQR: 64.4-79.04] vs. 84.35% [IQR: 81.2-86.7], p = 0.001) and higher percent of both intermediate and non-classical cells, yet without statistical significance (median 6.54% [IQR: 5.14-16.64] vs. 5.87% [IQR: 4.48-8.6], p = 0.37 and median 5.99% [IQR: 3.39-11.5] vs. 5.26% [IQR: 3.62-6.2], p = 0.42, respectively). In AMI patients both, analyzed plasma miRNA concentrations were higher than in healthy subjects (miR-146: median 5.48 [IQR: 2.4-11.27] vs. 1.84 [IQR: 0.87-2.53], p = 0.003; miR-155: median 25.35 [IQR: 8.17-43.15] vs. 8.4 [IQR: 0.08-16.9], p = 0.027, respectively), and returned back to the values found in the control group in follow-up. miR-155/miR-146 ratio correlated with the frequencies of classical monocytes (r=0.6, p = 0.01) and miR-155 correlated positively with the concentration of inflammatory cytokines - IL-6 and TNF-α. CONCLUSIONS: These results may suggest cooperation of both pro-inflammatory and anti-inflammatory signals in AMI in order to promote appropriate healing of the infarcted myocardium.
Authors: David Schumacher; Adelina Curaj; Sakine Simsekyilmaz; Andreas Schober; Elisa A Liehn; Sebastian F Mause Journal: Int J Mol Sci Date: 2021-05-22 Impact factor: 5.923